The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 20, 2024

Filed:

Jun. 11, 2021
Applicant:

Molecular Templates, Inc., Austin, TX (US);

Inventors:

Eric Poma, New York, NY (US);

Erin Willert, Round Rock, TX (US);

Garrett Lee Robinson, Austin, TX (US);

Sangeetha Rajagopalan, Round Rock, TX (US);

Brigitte Brieschke, Austin, TX (US);

Assignee:

Molecular Templates, Inc., Austin, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); A61K 39/00 (2006.01); C07K 14/245 (2006.01); C07K 14/25 (2006.01); C07K 16/08 (2006.01); C07K 16/10 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12N 9/10 (2006.01); C12N 9/24 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
C07K 14/25 (2013.01); C07K 14/245 (2013.01); C07K 16/00 (2013.01); C07K 16/085 (2013.01); C07K 16/088 (2013.01); C07K 16/1063 (2013.01); C07K 16/286 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/2887 (2013.01); C07K 16/32 (2013.01); C12N 9/1077 (2013.01); C12N 9/2497 (2013.01); C12N 15/62 (2013.01); C12Y 204/02036 (2013.01); C12Y 302/02022 (2013.01); A61K 2039/6037 (2013.01); C07K 2319/04 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C07K 2319/55 (2013.01);
Abstract

The present invention relates to Shiga toxin effector polypeptides with reduced antigenic and/or immunogenic potential. Immunogenicity can be a limitation for the repeated administration to mammals of proteins and polypeptides derived from Shiga toxins. The Shiga toxin effector polypeptides of the present invention have uses as components of therapeutics, diagnostics, and immunization materials. The cytotoxic proteins of the present invention have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, immune disorders, and microbial infections. The proteins of the present invention also have uses for detecting specific cell types, collecting diagnostic information, and monitoring the treatment of a variety of diseases, such as, e.g., cancers, immune disorders, and microbial infections.


Find Patent Forward Citations

Loading…